Dana-Farber and Brigham and Women's Hospital researchers engineer nanoparticles to prevent bone cancer, strengthen bones
- Posted: July 1, 2014
A research collaboration between Dana-Farber Cancer Institute and Brigham and Women’s Hospital (BWH) has utilized nanomedicine technologies to develop a drug-delivery system that can precisely target and attack cancer cells in the bone, as well as increase bone strength and volume to prevent bone cancer progression. The study is published the week of June 30, 2014 in Proceedings of the National Academy of Sciences.
Click here to read the full press release.
Among the research institutions NCI funds across the United States, it currently designates 68 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.